Product News

Forest Laboratories, Inc. (NYSE: FRX), today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) annual meeting scheduled May 18-22, 2013, in San Francisco, CA. Data on cariprazine, an investigational antipsychotic agent, provides details from Phase 3 trials for schizophrenia and acute mania in bipolar I disorder, as well as a long-term safety more...

Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered in the Pressair^® (Genuair^® outside the USA) inhaler.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) announced today that LINZE more...

Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on cariprazine at the American College of Neuropsychopharmacology Annual Meeting scheduled December 2-6, 2012 in Hollywood, FL. Forest Laboratories, Inc recently submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for cariprazine for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with Bipolar more...

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical company, and Adamas Pharmaceuticals, Inc. announced today that they have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR® (memantine HCl extended release) and donepezil HCl as a once daily therapy for the treatment of moderate to severe dementia of the Alzheimer’s type in the United States.

Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories today announced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran was discovered by Pierre Fabre and jointly developed by Forest Laboratories and Pierre Fabre, under a more...

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) will be hosting a conference call to discuss the U.S. Food and Drug Administration (FDA) approval of LINZESS™  at 4:00 p.m. Eastern Time on Thursday, August 30, 2012. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 26759985. more...

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, and Nabriva Therapeutics announced today that they have entered into an agreement for the development of Nabriva’s novel antibacterial agent, BC-3781. Pursuant to the agreement, Forest will provide Nabriva with $25 million, and fund and conduct in collaboration with Nabriva, certain development activities related to BC-3781 over the next 12 months. more...

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will more...

Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Medicament today announced additional positive results from a Phase III clinical trial of levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder (MDD). Treatment with levomilnacipran significantly reduced depression symptoms in patients with MDD compared to placebo, as measured by the Montgomery-Asberg Depression Rating Scale - Clinician Rated ( more...

Forest Laboratories, Inc. (NYSE: FRX) today announced that Forest Laboratories Holdings Limited (Forest), its wholly owned subsidiary, and Janssen Pharmaceutica NV (Janssen) entered into an agreement under which Forest acquired all U.S. patents and other U.S. and Canadian intellectual property for Bystolic^® (nebivolol), which is currently approved in the United States for the treatment of hypertension, thereby eliminating all future royalties. more...

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P. aeruginosa. The pivotal clinical study of Colobreathe demonstrated the benefits and its ability more...